目的 探索消癌平注射液联合PP化疗方案治疗中晚期肺腺癌患者的临床疗效。方法 选取淮南东方医院集团总医院于2021年1月—2023年12月收治的78例肺腺癌（LUAD）患者，按随机原则分为对照组与治疗组，每组各39例。对照组患者静脉滴注注射用培美曲塞二钠，500 mg/m²，静脉滴注1 h，顺铂注射液75 mg/m²，静脉滴注3 h。治疗组患者在对照组基础上静脉滴注消癌平注射液，60 mL/次，用5%葡萄糖注射液稀释至500 mL后滴注，连续滴注7 d，1次/d。21 d为1个周期，共治疗6个周期。观察两组患者临床疗效，比较治疗前后两组患者Piper疲乏修订量表，QLQ-C30生活质量评分，肿瘤标志物癌胚抗原（CEA）和细胞角蛋白19片段（CYFRA21-1）水平，及不良反应情况。结果 治疗组在客观缓解率上优于对照组（66.67% vs 43.59%，P＜0.05）。治疗3个周期后，治疗组患者Piper疲乏修订量表评分较治疗前显著下降（P＜0.05）。治疗6个周期后，两组患者较治疗前评分显著下降（P＜0.01），治疗组患者癌因性疲乏评分显著低于对照组（P＜0.05），治疗6个周期后，治疗组患者生活质量评分高于治疗前（P＜0.05），且高于对照组（P＜0.05）。治疗后，两组患者肿瘤标志物CEA、CYFRA21-1均显著下降（P＜0.05、0.01），且治疗组CEA、CYFRA21-1均低于对照组（P＜0.05）。治疗组不良反应发生率显著低于对照组（P＜0.05）。结论 消癌平注射液联合PP化疗治疗中晚期肺腺癌患者具有显著协同增效减毒效果，在改善患者癌因性疲乏方面效果显著。

Objective To explore the clinical efficacy of Xiaoaiping Injection combined with PP chemotherapy in treatment of advanced lung adenocarcinoma. Methods Patients (78 cases) with advanced lung adenocarcinoma in General Hospital of Huainan Oriental Hospital Group from January 2021 to December 2023 were divided into control and treatment group according to the principle of randomization, and each group had 39 cases. Patients in the control group were iv administered with Pemetrexed Disodium for injection for 1 h, 500 mg/m², and they were iv administered with Cisplatin Injection for 3 h, 75 mg/m², 21 d was a cycle, and the total of 6 cycles of treatment were performed. Patients in the treatment group were iv administered with Xiaoaiping Injection on the basis of the control group for 7 d, 60 mL/time, added into 500 mL 5% glucose injection, once daily. After treatment, the clinical evaluations were evaluated, and the Piper Fatigue Scale-Revised score, QLQ-C30 quality of life, tumor markers CEA and CYFRA21-1, and adverse reaction in two groups before and after treatment were compared. Results The objective remission rate of the treatment group was better than that of the control group ( 66.67 % vs 43.59 %, P < 0.05 ). After 3 cycles of treatment, the scores of Piper Fatigue Scale-Revised in the treatment group were significantly decreased compared with those before treatment (P < 0.05). After 6 cycles of treatment, the scores of patients in two groups were significantly decreased compared with those before treatment (P < 0.01). The scores of cancer-related fatigue in the treatment group were significantly lower than those in the control group (P < 0.05). After 5 cycles of treatment, the scores of patients in the treatment group were higher than those before treatment (P < 0.05) and higher than those in the control group (P < 0.05). After treatment, the tumor markers CEA and CYFRA21-1 were significantly decreased in two groups (P < 0.05, 0.01), and CEA and CYFRA21-1 in the treatment group were lower than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Xiaoaiping Injection combined with PP chemotherapy has a significant synergistic effect of enhancing efficacy and reducing toxicity in the treatment of patients with advanced lung adenocarcinoma, and is effective in improving cancer-related fatigue in patients.

R979.1